Detalhe da pesquisa
1.
TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma.
J Pathol
; 263(2): 139-149, 2024 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-38380548
2.
Integration of CD4+ T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.
Cancer Sci
; 115(4): 1306-1316, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38402640
3.
Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer.
Br J Cancer
; 130(5): 852-860, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38212482
4.
Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.
Cancer Immunol Immunother
; 73(4): 66, 2024 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38430246
5.
TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Br J Cancer
; 126(9): 1310-1317, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-35039625
6.
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer.
Br J Cancer
; 126(11): 1581-1588, 2022 06.
Artigo
Inglês
| MEDLINE | ID: mdl-35165401
7.
Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Cancer Immunol Immunother
; 71(9): 2117-2126, 2022 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-35041031
8.
POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
Cancer Med
; 13(4): e6962, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-38457207
9.
RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
J Immunother
; 2024 May 27.
Artigo
Inglês
| MEDLINE | ID: mdl-38800996